TP53 rs121912654: Understanding the p.Arg248Trp Variant
The rs121912654 variant in the TP53 gene, also known as p.Arg248Trp, is a rare germline mutation. It is clinically classified as pathogenic and is strongly associated with Li-Fraumeni syndrome, a condition that significantly increases the risk of developing various malignancies.
What each genotype means
Typical risk profile
You carry two copies of the common reference allele at this position, indicating the absence of the p.Arg248Trp variant in your test results. This genotype is associated with normal baseline tumor suppressor function for this specific site in the TP53 gene and does not confer inherited risk for Li-Fraumeni syndrome. However, standard age-appropriate cancer screenings and general health recommendations still apply.
Carried by virtually 100% of individuals across all global populations.
Li-Fraumeni syndrome predisposing genotype
You carry one copy of the pathogenic missense variant c.742C>T (p.Arg248Trp) in the TP53 gene. In scientific literature, germline presence of this variant is classified as pathogenic and strongly predisposing to Li-Fraumeni syndrome, a hereditary cancer predisposition disorder associated with high lifetime risks for multiple early-onset primary malignancies including breast cancer, soft-tissue and bone sarcomas, brain tumors, and adrenocortical carcinomas. Individuals carrying this variant are recommended in clinical guidelines to consult a medical geneticist or genetic counselor to discuss specialized high-risk surveillance and risk-reduction strategies.
Extremely rare in the general population, with a germline allele frequency well below 0.001% (gnomAD MAF < 0.00001).
Homozygous pathogenic variant
You carry two copies of the pathogenic c.742C>T (p.Arg248Trp) alteration in the TP53 tumor suppressor gene. Homozygous germline inheritance of dominant pathogenic TP53 mutations is virtually undocumented in living populations and is presumed to be lethal or extremely severe during embryonic development. Because Li-Fraumeni syndrome follows an autosomal dominant pattern and homozygous findings in germline testing are exceedingly unusual, this result should be promptly verified by clinical diagnostic testing in consultation with a medical geneticist.
Virtually non-existent in population databases and clinical cohorts.
What is the rs121912654 Variant?
The rs121912654 variant is a specific genetic change located within the TP53 gene on chromosome 17. In scientific literature, this is often referred to as c.742C>T, which results in an amino acid substitution where arginine is replaced by tryptophan at position 248 (p.Arg248Trp). This specific location is within the DNA-binding domain of the p53 protein, a critical region for the protein's function. Because this domain is essential for the protein to bind to DNA and regulate gene expression, changes here can severely disrupt the normal activity of the p53 protein. This variant is categorized as a missense mutation, meaning the change in the DNA sequence leads to the production of a protein with an altered amino acid, which can impair its ability to act as a tumor suppressor.
The Role of the TP53 Gene
The TP53 gene provides instructions for making a protein called p53, which acts as a tumor suppressor. This protein is often described as the 'guardian of the genome' because it plays a vital role in maintaining cellular stability. When DNA damage occurs, the p53 protein helps determine whether the cell should repair the damage or undergo programmed cell death, known as apoptosis. By preventing cells with damaged DNA from dividing, p53 helps stop the development of tumors. When a germline mutation like rs121912654 occurs, the resulting p53 protein may lose its ability to effectively monitor the cell cycle or trigger apoptosis. This loss of function allows cells with genetic errors to continue dividing, which significantly increases the likelihood of cancer development over an individual's lifetime.
Clinical Associations and Evidence
Research consistently associates the rs121912654 variant with Li-Fraumeni syndrome (LFS), a rare, autosomal dominant disorder characterized by a high predisposition to a wide spectrum of cancers. Clinical evidence from databases like ClinVar classifies this variant as pathogenic, meaning there is strong consensus among experts that it contributes to disease. Individuals carrying this variant face an elevated risk of early-onset malignancies, including breast cancer, sarcomas, and brain tumors. Because LFS is highly penetrant, the presence of this variant is considered a significant clinical finding. It is important to note that while the association with LFS is well-documented, the specific cancer risk can vary between individuals. Clinical management for carriers typically involves intensive surveillance programs designed to detect potential malignancies at their earliest, most treatable stages.
Population Frequency
The rs121912654 variant is extremely rare in the general population. Data from large-scale genomic databases, such as gnomAD, indicate that this variant is not typically found in the general public, appearing at a frequency of approximately 0.0004% to 0.0009% in non-cancer datasets. Because it is so uncommon, it is not considered a common polymorphism. Its presence is usually identified in the context of clinical genetic testing for individuals or families with a history of early-onset or multiple primary cancers. Due to its rarity and high clinical significance, it is not a variant that would be expected in standard consumer-grade ancestry or wellness genetic reports. Its detection is almost exclusively associated with specialized diagnostic workflows in clinical genetics.
What This Information Means for You
If you have received information regarding this variant, it is essential to understand that this is a clinical-grade finding that requires professional interpretation. This variant is not a diagnosis of cancer, but rather a marker of increased genetic risk. If you are concerned about your genetic status or family history, the most appropriate step is to consult with a board-certified genetic counselor or a medical geneticist. These professionals can help you understand the implications of the variant, discuss the benefits and limitations of genetic testing, and explain the options for cancer surveillance. Do not attempt to interpret this information in isolation. Always discuss any genetic findings with a qualified healthcare provider who can provide personalized guidance based on your specific medical history and clinical context.
How common is this variant?
The rs121912654 variant is extremely rare, with a frequency of approximately 0.0004% to 0.0009% in general population databases.
Frequently asked questions
Is rs121912654 a diagnosis of cancer?
No, identifying this variant is not a cancer diagnosis. It indicates a germline predisposition to cancer, meaning there is a higher statistical risk of developing certain types of tumors over a lifetime.
What is Li-Fraumeni syndrome?
Li-Fraumeni syndrome is a rare, inherited disorder that significantly increases the risk of developing various types of cancer at a young age. It is primarily caused by pathogenic variants in the TP53 gene.
Should I be tested for this variant?
Genetic testing for TP53 variants is typically recommended only for individuals who meet specific clinical criteria, such as a strong family history of early-onset cancers. You should discuss your family history with a genetic counselor to determine if testing is appropriate for you.
Can I change my risk if I have this variant?
While you cannot change your genetic sequence, individuals with this variant often participate in specialized medical surveillance programs. These programs aim to detect cancers early, when they are most treatable.
Sources & further reading
Educational information only, last refreshed 10/18/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121912654?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in TP53
Pathogenic missense variant (p.Arg248Gln) associated with Li-Fraumeni syndrome.
Functional codon 72 polymorphism (Arg72Pro) affecting apoptotic capability and associated with differential susceptibility to multiple cancer types.
Functional 3' UTR polyadenylation signal polymorphism altering TP53 transcription termination, showing population-specific baseline carrier frequencies across global groups.
Pathogenic hotspot variant (p.Arg273His) in TP53 predisposing carriers to early-onset sarcomas, breast cancers, and leukemias.
Li-Fraumeni syndrome missense variant (p.Arg248Trp) causing loss of tumor suppressor function and multi-cancer predisposition.
Synonymous and regulatory variant in linkage with TP53 codon 72 that modulates blastocyst implantation competence and the risk of recurrent implantation failure.